This key provides the non-specialist with reference material to help recognise an invasive mosquito species and gives details on the morphology to help with verification.
Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.
European surveillance data show on-going transmission of viral hepatitis across the European Union and European Economic Area (EU/EEA). The available notification data however, do not provide a clear epidemiological picture of hepatitis C in Europe. Prevalence data from population surveys are a key source of information to complement the surveillance data for hepatitis C due to the limitations of surveillance for hepatitis: the infection is often asymptomatic and notifications are strongly influenced by local testing practices. The overarching aim of this toolkit is to gain a better understanding of the HCV epidemiology in the EU/EEA.
This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.
While the number of mosquito-borne diseases in Europe is currently low, there is an increasing trend in their global incidence and geographical distribution.
This handbook uses maps produced through the non-linear discriminate analysis methodology and interprets them to show the potential for Ae. albopictus to spread further in Europe.
ECDC has produced these guidelines which aim to support the implementation of tailored surveillance for invasive mosquito species of public health relevance.
This response plan is designed to prevent the spread of multidrug-resistant Neisseria gonorrhoeae (MDR NG) in the EU/EEA in the context of the possible emergence of untreatable gonorrhoea
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national strategies and programmes in countries in Europe in order to reduce and prevent infections among people who inject drugs.
The content of this joint guidance was developed by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the support of a technical advisory group composed of policy makers, service providers, civil society representatives and preventative health experts from throughout the EU/EEA.